A Phase 4 interventional study of levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-11-26.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 17th largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 4, and was the 9th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2003, is one of 6 in phase 4, and was the 13th registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Effect of adjunctive levetiracetam on polysomnography in adults with partial-onset epilepsy receiving a classical antiepileptic drug
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Changes from Baseline to visit 7 in percent REM, percent slow wave sleep (stages 3 and 4), and sleep efficiency (which is total sleep time ÷ time in bed defined as lights out), with particular focus on sleep efficiency.
Secondary endpoints are based on the changes from Baseline to visit 7
No study locations are listed for this record.
The record gives a start of Mar 2003, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam